Computer Vision Technology Delivered by Johnson Controls Sensormatic Solutions Powers a Portfolio of Outcome-Focused Analytics to Solve Retailers’ Evolving Challenges
Sensormatic Solutions, the leading global retail solutions portfolio of Johnson Controls, is demonstrating the full breadth of its computer vision analytics technology at EuroShop. Each of Sensormatic Solutions computer vision capabilities leverage proprietary deep learning algorithms and help retailers optimize labor allocation, strengthen loss prevention efforts, maintain safe environments for shoppers and associates, and gather insights on shopper experiences.
“Despite the technology’s relatively short time on the market, we’ve evolved its capabilities significantly, taking it from simple object detection to using complex behavior detection to identify and analyze shopper behavior,” said Subramanian Kunchithapatham (KS), chief technology officer at Sensormatic Solutions. “Computer vision’s unparalleled insights give retailers the power to enhance the store experience by automating specific tasks, which allow store associates to focus on valuable customer interactions.”
Maximize Conversion Opportunities with Shopper Engagement
Computer vision’s newest outcome-focused capabilities are designed to help retailers leverage shopper behavior data to improve conversion and optimize merchandise placement and floor design by leveraging in-store path-to-purchase pattern insights. The technology can also recognize impactful marketing partnership opportunities by identifying consumers’ buying choices and brand preferences throughout their journey.
Driving Operational Excellence by Allocating Labor to the Right Place at the Right Time
With labor shortages, computer vision analytics automates associate tasks and provides powerful insights that can help retailers identify the times and areas in which associates are most needed to help enhance the customer experience and drive sales, while reducing labor expenses.
With the popularity of omnichannel fulfillment options, like Click & Collect and curbside pick-up, retailers are seeking ways to fill these orders while minimizing labor hours spent searching for merchandise. Computer vision analytics enables exterior parking lot cameras to detect the arrival of customers to pre-determined areas, alerting associate in real-time to fulfill or deliver an order.
Insights Amplify Proactive Loss Prevention and Liability Programs
Computer vision can amplify solutions used today to help mitigate shrink by enabling more proactive and preventative measures to deter theft, detect Organized Retail Crime (ORC) activity, and help protect people and assets through real-time monitoring of suspicious and criminal behavior.
Sensormatic Solutions computer vision technology leverages existing video infrastructure investments and is easy to deploy. "While many retailers already depend on cameras for surveillance, they can now leverage our computer vision analytics by tapping into that same infrastructure to unlock a world of new capabilities that help drive sales, reduce risk, optimize labor and enhance the customer experience," continued Kunchithapatham.
To learn more about Sensormatic Solutions computer vision analytics, visit stand C01 in Hall 6 at Trade Fair Düsseldorf between 26 February – 2 March 2023 and follow #Sensormatic on Twitter and LinkedIn. To request a booth tour or a meeting with an account manager, visit the Sensormatic Solutions EuroShop Page.
About Johnson Controls
At Johnson Controls (NYSE:JCI), we transform the environments where people live, work, learn and play. As the global leader in smart, healthy and sustainable buildings, our mission is to reimagine the performance of buildings to serve people, places and the planet.
Building on a proud history of nearly 140 years of innovation, we deliver the blueprint of the future for industries such as healthcare, schools, data centers, airports, stadiums, manufacturing and beyond through OpenBlue, our comprehensive digital offering.
Today, with a global team of 100,000 experts in more than 150 countries, Johnson Controls offers the world`s largest portfolio of building technology and software as well as service solutions from some of the most trusted names in the industry.
Visit http://www.johnsoncontrols.com for more information and follow @Johnson Controls on social platforms.
About Sensormatic Solutions
Sensormatic Solutions is the leading global retail solutions portfolio of Johnson Controls powering operational excellence at scale and enabling smart and connected shopper engagement. Our intelligent digital operating platform – Sensormatic IQ – combines the full Sensormatic Solutions portfolio, including third-party data to deliver unmatched insights into shopper experience, inventory intelligence, loss prevention and operational effectiveness with advanced technologies, like AI and Machine Learning. This enables retailers to act on prescriptive and predictive data-driven outcomes to confidently move into the future. Please visit Sensormatic Solutions or follow us on LinkedIn, Twitter, and our YouTube channel.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230223005006/en/
Contact information
Katarzyna Breczko
Sensormatic Solutions by Johnson Controls
Work: +49 173 7070 562
katarzyna.breczko@jci.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
